In the second-line therapy of NSCLC, elderly patients (those aged 75 years and over) appeared to tolerate anti-PD1/PDL1 and Grade 3 or 4 treatment-related adverse events were less frequent compared to the sub-group of patients below 65 years of age (Marur et al., 2018). This evidence concerns the gene CD274 and non-small cell lung carcinoma.